A case of exacerbated encephalopathy with stroke-like episodes and lactic acidosis triggered by metformin in a patient with MELAS.
DNA, Mitochondrial
MELAS syndrome
Metformin
Point mutation
Seizures
Journal
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
ISSN: 1590-3478
Titre abrégé: Neurol Sci
Pays: Italy
ID NLM: 100959175
Informations de publication
Date de publication:
24 Jan 2024
24 Jan 2024
Historique:
received:
13
12
2023
accepted:
19
01
2024
medline:
24
1
2024
pubmed:
24
1
2024
entrez:
24
1
2024
Statut:
aheadofprint
Résumé
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a maternally inherited multisystemic disorder caused by mutations in mitochondrial DNA that result in cellular energy deficiency. MELAS affects the most metabolically active organs, including the brain, skeletal muscles, cochlea, retina, heart, kidneys, and pancreas. As a result, about 85% of carriers of m.3243A > G, the most common mutation in MELAS, develop diabetes by the age of 70. Although metformin is the most widely prescribed drug for diabetes, its usefulness in mitochondrial dysfunction remains controversial. Here, we present the case of a 32-year-old Korean patient diagnosed with MELAS who presented with exacerbated stroke-like episodes and lactic acidosis triggered by metformin.
Identifiants
pubmed: 38265537
doi: 10.1007/s10072-024-07343-9
pii: 10.1007/s10072-024-07343-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. Fondazione Società Italiana di Neurologia.
Références
Maassen JA, Janssen GM, t Hart LM (2005) Molecular mechanisms of mitochondrial diabetes (MIDD). Ann Med 37(3):213–221
Tong HF, Lee HH, Tong TT, Lam SF, Sheng B, Chan KW, Li JK, Tam HV, Ching CK (2022) Neurological manifestations in m.3243A>G-related disease triggered by metformin. J Diabetes Complicat 36(3):108111
Chen WT, Lin YS, Wang YF, Fuh JL (2019) Adult onset MELAS syndrome presenting as a mimic of herpes simplex encephalitis. Acta Neurol Taiwan 28(2):46–51
Kim NH, Siddiqui M, Vogel J (2021) MELAS syndrome and MIDD unmasked by metformin use: a case report. Ann Intern Med 174(1):124–125
doi: 10.7326/L20-0292
pubmed: 32833489
Lin WH, Yang IH, Cheng HE, Lin HF (2022) Case report: late-onset mitochondrial disease uncovered by metformin use in a patient with acute verbal auditory agnosia. Front Neurol 13:863047
doi: 10.3389/fneur.2022.863047
pubmed: 35401420
pmcid: 8990297
Murakami K, Sakamoto K, Ishiguchi H, Ito H (2023) Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes diagnosed after metformin-triggered stroke-like episodes. J Stroke Cerebrovasc Dis 32(5):107080
doi: 10.1016/j.jstrokecerebrovasdis.2023.107080
pubmed: 36933522
Fontaine E (2018) Metformin-induced mitochondrial complex i inhibition: facts, uncertainties, and consequences. Front Endocrinol (Lausanne) 9:753
doi: 10.3389/fendo.2018.00753
pubmed: 30619086
Madiraju AK, Erion DM, Rahimi Y, Zhang X-M, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald MJ, Jurczak MJ, Camporez J-P, Lee H-Y, Cline GW, Samuel VT, Kibbey RG, Shulman GI (2014) Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510(7506):542–546
doi: 10.1038/nature13270
pubmed: 24847880
pmcid: 4074244
Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, Ray JE, Timmins P, Williams KM (2011) Clinical pharmacokinetics of metformin. Clin Pharmacokinet 50(2):81–98
doi: 10.2165/11534750-000000000-00000
pubmed: 21241070
Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron B, Stanifer J, Mock CK, Kosinski A, Wang X, Tang S, Williams JW (2016) Metformin use in patients with historical contraindications or precautions. Department of Veterans Affairs (US), Washington (DC)